STXS

Stereotaxis, Inc. 10-Q Summary: Period Ended June 30, 2006

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., a medical device company designing and marketing the Stereotaxis System for magnetic navigation of catheters in interventional cardiology. The report covers the three and six-month periods ended June 30, 2006. The company is an accelerated filer incorporated in Delaware.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 38% year-over-year for the quarter and 51% for the six-month period. This was driven by a drop in system sales (3 units delivered in Q2 2006 vs. 6 in Q2 2005). Conversely, revenue from disposables, service, and accessories increased 40% (quarter) and 49% (six months) due to a growing installed base.
• Operating Expenses: Operating expenses increased significantly. Research and Development (R&D) rose 43% (quarter) and 52% (six months) due to new projects and platform development. Sales and Marketing expenses increased 33% (quarter) and 39% (six months) due to hiring and expanded programs.
• Stock-Based Compensation: The company adopted SFAS 123(R) effective January 1, 2006, resulting in approximately $1.2 million (quarter) and $2.1 million (six months) in share-based compensation expense, contributing to higher operating costs.
• Liquidity Improvement: Cash and cash equivalents increased from $3.6 million at year-end 2005 to $31.1 million at June 30, 2006, primarily due to a public offering of 5.5 million shares in February 2006 yielding approximately $61.9 million in net proceeds.
• One-Time Items: The prior year period included a $2.9 million royalty settlement expense related to a patent dispute with the University of Virginia, which did not recur in 2006.

Guidance, Outlook, and Risks

• Outlook: Management expects negative cash flow from operations to continue through most of 2007. R&D and SG&A expenses are expected to increase to support product commercialization and regulatory requirements.
• Liquidity: The company believes existing cash, cash equivalents, and investments ($44.7 million total) are sufficient to fund operations for the next 12 months. However, additional financing may be required, which could be dilutive.
• Backlog: Purchase orders and commitments for the magnetic navigation system were approximately $40.0 million as of June 30, 2006. Management notes these are subject to contingencies and may be revised or canceled.
• Risks: Key risks include the failure to obtain FDA clearances for new disposable devices, reliance on collaboration partners (Siemens, Philips, Biosense Webster), long sales and installation cycles, and the potential for product liability claims. The company also faces currency fluctuation risks as it operates internationally.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the status of the $40 million backlog and the likelihood of conversion to revenue given the long installation cycles and potential for order cancellations.
• Regulatory Approvals: Confirm the status of FDA 510(k) clearances for new disposable interventional devices, which are critical for future revenue growth.
• Burn Rate and Runway: Assess the sustainability of the current cash burn rate (~$26.8 million used in operations for six months) against the $44.7 million cash position to determine the need for future capital raises.
• Collaboration Dependencies: Review the terms and stability of partnerships with Siemens, Philips, and Biosense Webster, as a significant portion of system sales relies on these integrations.
• Stock-Based Compensation Impact: Monitor the impact of SFAS 123(R) adoption on future earnings, noting $9.4 million of unrecognized compensation cost remaining to be amortized over four years.